
-
Daré Bioscience, Inc. NASDAQ:DARE Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Location: San Diego, California, United States | Website: www.darebioscience.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
11.23M
Cash
15.7M
Avg Qtr Burn
N/A
Short % of Float
1.00%
Insider Ownership
1.57%
Institutional Own.
8.84%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
XACIATO (DARE-BV1) Details Bacterial infection | Approved Quarterly sales | |
Ovaprene® Details Contraceptive | Phase 3 Data readout | |
Sildenafil Cream, 3.6% Details Sexual dysfunction, Sexual desire disorder | Phase 3 Initiation | |
DARE-VVA1 (Tamoxifen formulation) Details Vulvovaginal Candidiasis | Phase 2 Initiation | |
DARE-PDM1 Details Primary dysmenorrhea | Phase 1 Update | |
DARE-PTB1 Details Preterm birth | Phase 1 Initiation | |
DARE-HRT1 Details Menopause | IND Submission |